Barclays’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-48,607
| Closed | -$8.74M | – | 7353 |
|
|
2017
Q3 | $8.74M | Buy |
48,607
+44,533
| +1,093% | +$6.21M | 0.01% | 1139 |
|
|
2017
Q2 | $423K | Buy |
4,074
+969
| +31% | +$79.1K | ﹤0.01% | 3682 |
|
|
2017
Q1 | $244K | Sell |
3,105
-16,768
| -84% | -$1.04M | ﹤0.01% | 4117 |
|
|
2016
Q4 | $891K | Sell |
19,873
-13,758
| -41% | -$675K | ﹤0.01% | 2861 |
|
|
2016
Q3 | $1.88M | Buy |
+33,631
| New | +$1.87M | ﹤0.01% | 2058 |
|
|
2016
Q2 | – | Sell |
-3,563
| Closed | -$160K | – | 6863 |
|
|
2016
Q1 | $160K | Buy |
3,563
+790
| +28% | +$38.3K | ﹤0.01% | 4008 |
|
|
2015
Q4 | $169K | Sell |
2,773
-465
| -14% | -$32.7K | ﹤0.01% | 4042 |
|
|
2015
Q3 | $178K | Buy |
3,238
+2,606
| +412% | +$164K | ﹤0.01% | 4215 |
|
|
2015
Q2 | $38K | Sell |
632
-35,189
| -98% | -$2.01M | ﹤0.01% | 5325 |
|
|
2015
Q1 | $2.04M | Buy |
35,821
+34,956
| +4,041% | +$2.34M | ﹤0.01% | 2297 |
|
|
2014
Q4 | $50K | Buy |
+865
| New | +$36.4K | ﹤0.01% | 5729 |
|
Barclays's KITE Position: Q4 2017 in Review
Barclays sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 48,607 shares — an estimated $8.74M sold.
Barclays first reported a position in KITE in Q4 2014 and held it in 11 quarters. The position peaked at $8.74M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Barclays reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Barclays sold 48,607 Kite Pharma, Inc. shares in Q4 2017, an estimated $8.74M.
- Barclays first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 11 quarters.
- Barclays's Kite Pharma, Inc. position peaked at $8.74M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Barclays's 13F filing for Q4 2017, filed 14 Feb 2018.